Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.

PI3K inhibitor in the combination with ICB with the optimized protocol fine-tuned T cell activation signaling for antitumor immunity via decreasing Tregs and optimizing memory CD8+ T cell responses, illustrating a promising combination therapy.